loader from loading.io

Dermatologic Care in the Sexual + Gender Diverse Patient with Klint Peebles, MD

DermDocs

Release Date: 08/03/2022

IL-31 Mechanism of Action and Clinical Implications for Prurigo Nodularis show art IL-31 Mechanism of Action and Clinical Implications for Prurigo Nodularis

DermDocs

This is the second episode of a two-part miniseries, "IL-31 Inhibition for Treatment of Prurigo Nodularis" series, supported by an educational grant from Galderma. Hosted by expert dermatologist and neuroscientist Dr. Sarina Elmariah, MD, PhD, MPH, this episode, "IL-31 Mechanism and Clinical Implications for PN", featuring Dr. Shawn Kwatra, discusses the following topics: Mechanism of action for IL-31 inhibitor nemolizumab Clinical safety and efficacy data for nemolizumab for treatment of PN Strategies for prescribing IL-31 inhibitors in clinical practice Pearls for patient selection...

info_outline
Exploring the Latest Updates in the Epidermolysis Bullosa Treatment Landscape show art Exploring the Latest Updates in the Epidermolysis Bullosa Treatment Landscape

DermDocs

This is the second episode of a two-part educational series to raise awareness of epidermolysis bullosa (EB) and the latest FDA-approved treatment options for this disease. Our host, Dr. Michael Lavery, a Pediatric Dermatologist and Clinical Assistant Professor at the University of Florida in Gainesville, FL, is joined by Dr. Joyce Teng, MD, PhD, Professor of Dermatology and Pediatrics at Stanford University School of Medicine in Stanford, CA, as they discuss the following topics: Setting the stage for treating a patient with EB Assessing EB severity and subtype to inform treatment ...

info_outline
Achieving More: How and When to Switch Systemic Therapies in Atopic Dermatitis? show art Achieving More: How and When to Switch Systemic Therapies in Atopic Dermatitis?

DermDocs

This is the sixth episode of our ongoing "Program on JAK Inhibitors for Atopic Dermatitis" series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "Achieving More: How and When to Switch Systemic Therapies in Atopic Dermatitis?", featuring Beth Sweney, PA-C discusses the following topics: Challenges in achieving treatment targets in AD Therapeutic inertia and clinical implications of inadequate response Comparative clinical data evaluating upadacitinib and dupilumab for treatment of AD Transitioning to systemic therapies from topical agents,...

info_outline
Exposing the Epidermolysis Bullosa Patient Burden and Challenges in Disease Management show art Exposing the Epidermolysis Bullosa Patient Burden and Challenges in Disease Management

DermDocs

This is the first episode of a two-part educational series to raise awareness of epidermolysis bullosa (EB) and the latest FDA-approved treatment options for this disease. Our host, Dr. Joyce Teng, MD, PhD, Professor of Dermatology and Pediatrics at Stanford University School of Medicine in Stanford, CA, is joined by Dr. Michael Lavery, a Pediatric Dermatologist and Clinical Assistant Professor at the University of Florida in Gainesville, FL, as they discuss the following topics: Epidemiology and prevalence of EB Burden of disease and impact on patients' quality of life Gaps and...

info_outline
Chronic Hand Eczema: All Hands on Deck show art Chronic Hand Eczema: All Hands on Deck

DermDocs

This podcast episode, sponsored by Leo Pharma, features LiVDerm faculty and esteemed dermatologists Dr. Christopher Bunick, MD, PhD, and Dr. Jonathan Silverberg, MD, PhD, MPH. As experts in all things concerning eczema, our faculty discuss the differentiating features and disease burden in patients suffering from chronic hand eczema (CHE) and review the current guidance for treatment, including these specific topics: Differentiating CHE from atopic dermatitis of the hands, including triggers, pathophysiology, and clinical presentation Expert guidance for accurate diagnosis and work-up of...

info_outline
Examining the Gaps and Challenges in Diagnosing and Treating Prurigo Nodularis show art Examining the Gaps and Challenges in Diagnosing and Treating Prurigo Nodularis

DermDocs

This is the first episode of a two-part miniseries, "IL-31 Inhibition for Treatment of Prurigo Nodularis" series, supported by an educational grant from Galderma and hosted by prurigo nodularis (PN) expert Dr. Shawn Kwatra, MD. This episode, "Examining the Gaps and Challenges in Diagnosing and Treating Prurigo Nodularis", featuring expert dermatologist and neuroscientist Dr. Sarina Elmariah, MD, PhD, MPH, discusses the following topics: The lack of awareness and timely, correct diagnosis of PN patients Strategies for assessing patients with PN and alleviating disease symptoms and burden ...

info_outline
Skirting Steroids in Atopic Dermatitis: New Therapies and Expert Strategies for Long-term Control show art Skirting Steroids in Atopic Dermatitis: New Therapies and Expert Strategies for Long-term Control

DermDocs

This is the second episode of a two-part activity on "Skirting Steroids in Atopic Dermatitis", supported by an educational grant from Arcutis Biotherapeutics, Inc., and hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "New Therapies and Expert Strategies for Long-term Control", featuring expert dermatologist Dr. Jonathan Silverberg, MD, PhD, MPH, discusses the following topics: The pros and cons of steroid use in treating AD Targeted non-steroidal topical therapies approved by the FDA Relevant clinical efficacy and safety data for new and emerging...

info_outline
Choosing the Right Path: JAK Inhibitors or Biologics for Atopic Dermatitis? show art Choosing the Right Path: JAK Inhibitors or Biologics for Atopic Dermatitis?

DermDocs

This is the fifth episode of our new "Program on JAK Inhibitors for Atopic Dermatitis" series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "Choosing the Right Path: JAK Inhibitors or Biologics for Atopic Dermatitis?", featuring expert dermatologist Dr. Naiem Issa, MD, PhD, discusses the following topics: Mechanistic differences between JAKi and biologics for treatment of AD Clinical data supporting the safety of JAKi in head-to-head trials compared to biologics Pearls for prescribing JAKi to AD patients Strategies for choosing JAKi vs biologics based...

info_outline
Skirting Steroids in Atopic Dermatitis: Dangers and Side Effects of Steroid Exposure in Treatment of AD show art Skirting Steroids in Atopic Dermatitis: Dangers and Side Effects of Steroid Exposure in Treatment of AD

DermDocs

This is the first episode of a two-part activity on "Skirting Steroids in Atopic Dermatitis", supported by an educational grant from Arcutis Biotherapeutics, Inc., and hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "Dangers and Side Effects of Steroid Exposure in Treatment of AD", featuring expert dermatologist Dr. Peter Lio, MD, discusses the following topics: Side effects of topical and oral corticosteroid exposure Pearls and gaps in current guidelines for treatment of AD Identifying topical steroid withdrawal symptoms Safety and stewardship strategies...

info_outline
Setting the Stage: Effective Onboarding of your AD Patients onto JAK Inhibitor Therapy show art Setting the Stage: Effective Onboarding of your AD Patients onto JAK Inhibitor Therapy

DermDocs

This is the fourth episode of our new "Program on JAK Inhibitors for Atopic Dermatitis" series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "Setting the Stage: Effective Onboarding of your AD Patients onto JAK Inhibitor Therapy", featuring expert dermatologist Dr. Ruth Ann Vleugels, MD, MPH discusses the following topics: Identifying ideal candidates for oral JAK inhibitor therapy Steps to initiate therapy and onboard new patients How to manage side effects and maintain adherence to treatment Case examples and real-world data

info_outline
 
More Episodes

We are honored to speak to Klint Peebles, MD, the chair of LiVDerm's Sexual and Gender Diverse Dermatology Summit: Fundamentals and Practical Pearls and past chair of the American Academy of Dermatology’s Expert Resource Group on Sexual and Gender Diverse Health. Dr. Peebles, a board-certified dermatologist with Kaiser Permanente, Mid-Atlantic Permanente Medical Group, has extensive clinical, leadership, and research expertise in sexual and gender diverse health and gender-affirming dermatology. Dr. Peebles currently serves on the LGBTQ Health Specialty Section Council of the American Medical Association. Dr. Peebles mentions some of the key reasons why you don't want to miss the Sexual and Gender Diverse Dermatology Summit: Fundamentals and Practical Pearls in California October 15-16, 2022! - Register here: www.livderm.org/live-events/sexual-and-gender-minority/

Topics Dr. Peebles covers include:

  • We are so excited to welcome you as the conference chair of our upcoming Sexual and Gender Diverse Dermatology Summit in Southern California this October 15-16. What unique experiences do you bring to this conference and why is this patient population so important in the dermatologic field?
  • Although there are certain aspects of aesthetic medicine in caring for sexual and gender diverse patients, would you consider this area of the discipline falling under the category of medical dermatology, or is it not necessary to differentiate? Do you expect practitioners of both cosmetic and general dermatology to benefit from the Summit?
  • Your wealth of experience, leadership, and advocacy in the field of better medical care for the sexual and gender diverse patient population has no doubt improved outcomes and quality of life. Can you tell us about some of your career highlights and moments when you could see actionable change as a result of your efforts?
  • The Sexual and Gender Diverse Summit, taking place within SBS: West Coast Derm this October 2022 at the Terranea Resort is a milestone event for LiVDerm. Do you think the location of the event just outside of Los Angeles, California, is indicative of the sexual and gender diverse population and the providers who see them? Do you see events like this someday soon being held in smaller, more rural regions of the U.S. where fewer resources or social determinants may mean that sexual and gender diverse patients face even larger roadblocks to care?
  • Is the field of dermatology seeing improvements in nondiscrimination, acceptance, welcoming environments, affirming language, and dedicated initiatives to improve safety, and can you explain some of those efforts within the context of guidelines or policy?

www.livderm.org